Literature DB >> 21709627

Phage therapy of Cronobacter-induced urinary tract infection in mice.

Lubomíra Tóthová1, Peter Celec, Janka Bábíčková, Jana Gajdošová, Hend Al-Alami, Natália Kamodyova, Hana Drahovská, Adriana Liptáková, Ján Turňa, Július Hodosy.   

Abstract

BACKGROUND: Cronobacter spp. is an opportunistic pathogen causing rare but dangerous cases of meningitis, sepsis and urinary tract infection. Phage therapy overcomes antibiotic resistance and represents an alternative approach to standard antimicrobial treatment. There are no published studies on the use of phages against Cronobacter spp. in vivo. The aim of our study was to prove the effects of isolated Cronobacter-specific phages on renal colonization in a model of urinary tract infection in mice. MATERIAL/
METHODS: Urinary tract infection was induced by transurethral application of Cronobacter turicensis (1011 CFU/ml). Simultaneously, isolated Cronobacter-specific phages were administered intraperitoneally (1011 PFU/ml). After 24 hours, kidneys and bladder were collected and used for cultivation and analysis of gene expression and oxidative stress markers.
RESULTS: Phage therapy reduced the number of Cronobacter colonies in the kidney by 70%. Higher levels of malondialdehyde were reduced by phage therapy without affecting the antioxidant status. The expression of pro-inflammatory cytokines tumor necrosis factor-alpha and monocyte chemoattractant protein-1 increased by the infection and was attenuated by phage therapy.
CONCLUSIONS: Phage therapy proved effective in the prevention of ascending renal infection in a murine model of urinary tract infection. Long-term effects and safety of the treatment are currently unknown. Further studies should test phage therapy in other Cronobacter infection models.

Entities:  

Mesh:

Year:  2011        PMID: 21709627      PMCID: PMC3539570          DOI: 10.12659/msm.>16271

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


Background

Cronobacter spp. (previously known as Enterobacter sakazakii) is a Gram-negative opportunistic pathogen belonging to the Enterobacteriaceae family. It is known to cause serious infections including bacteremia, enterocolitis, meningitis and even sepsis, especially in premature newborns [1]. Recently, a case study reporting cystitis caused by C. sakazakii in the elderly has been published [2]. The lethality of Cronobacter infections is very high (40–80%) and the incidence is relatively low (8.7 per 100 000 low birth weight neonates) [3,4]; however, it is assumed that the number of infections caused by Cronobacter is underreported. Antibiotic therapy is effective if applied soon after infection, but resistance against some therapeutics has already been reported [5]. It can be expected that alternative approaches will be needed soon, since the antimicrobial resistance is rising [6]. Powdered milk formulas are an important source of Cronobacter infections [7]. The resistance of Cronobacter strains to higher temperature and osmotic stress during desiccation enables their survival in dried food [8]. Other virulence factors include production of proteases, endotoxins and outer membrane proteins [9,10]. In addition, Cronobacter strains have adhesive properties and are able to invade human cells [11,12]. The current threat of antibiotic resistance has led to re-evaluation of bacteriophages as antibacterial agents potentially usable for treatment and/or prevention of bacterial infections [13,14]. Advantages of this approach are the specificity of phages bypassing the collateral damage induced by antibiotics on natural microflora, and the virtually single-administration efficacy of lytic phages. Phage therapy of staphylococcal and enterococcal infections has already been tested in clinical trials, with few reported unwanted side effects independent of the route of application [15,16]. Studies testing phage cocktails for the treatment of chronic venous leg ulcers and chronic ear infection are currently in progress [17,18]. Additionally, promising results of animal experiments show that phages might play a role in the biocontrol of pathogens in clinical medicine [19]. It has been demonstrated in vitro that contamination of powdered milk formulas with Cronobacter can be effectively eliminated with selected Cronobacter-specific phages [20,21]. To our knowledge, the potential of phage therapy to control Cronobacter infection in animal models of human diseases has not yet been tested; therefore the aim of our study was to prove the effects of phage therapy on Cronobacter-induced urinary tract infection (UTI) in a murine model.

Material and Methods

Bacterial strains and phages

The bacterial strain used in this study was isolated from a food matrix (obtained from Food Research Institute, Bratislava) in Luria-Bertani (LB) medium overnight at 37°C. The Strain C. turicensis 290708/07 was identified using the biochemical API 20E identification system (Biomerieux, Marcy-l’Etoile, France) and characterized by molecular methods as described in detail by Turcovsky et al. [22]. This strain was used as a representative Cronobacter spp. strain for phage propagation, isolation and examination throughout the study. For in vivo experiments, bacteria were centrifuged (6000 g/10 min/4°C) after overnight cultivation and resuspended in phosphate buffer saline (PBS). The number of colony-forming units was determined by standard plate counts of serial dilutions on LB agar or MacConkey agar plates. Phages used in the study were isolated from sewage collected from 2 wastewater treatment plants in Petržalka and Devínska Nová Ves, Bratislava, Slovakia (further in text as P2, D2, respectively). Pure phage cultures were obtained by repeated isolation from single plaques grown on indicator strain in double agar overlay plates. Phages were further purified by ultracentrifugation on the sucrose gradient. A mixture of the 2 phages with the highest lytic activity toward the indicator strain was used in the in vivo experiment.

In vitro specificity of phages

The ability of phages to infect different strains was assessed by the spot test. Incubated indicator bacterial lawns were dropped with 10 μl (108 PFU/ml) of phage preparation, following incubation at 37°C overnight. On the next day, bacterial lawns were examined for lysis zones. The bacterial strains used in this test contained – 10 E. coli strains, 24 Enterobacter cloacae strains, 2 Citrobacter strains and 7 different Salmonella enterica strains.

Animal model of urinary tract infection

Forty-seven C57BL/6NCrl 10–11-week-old female mice were used for the experiment (AnLab Ltd., Prague, Czech Republic). Animals were housed in a room with a 12/12 h light dark cycle and had ad libitum access to water and food pellets. Animals were divided into 4 groups as follows: CRONO (n=13) with C. turicensis transurethral application, CRONO-PHAGE (n=14) with C. turicensis transurethral application and intraperitoneal phage administration, PHAGE (n=10) with intraperitoneal phage administration and a CTRL group (n=10) as a mock-infected control group. All experiments were approved by the Ethics Committee of the Institute of Molecular Biomedicine, Comenius University in Bratislava, Slovakia. UTI was modeled according to a recently published protocol [23]. The mice were briefly anaesthetized with isoflurane and instilled via 28G plastic transurethral catheters (outer diameter 0.35 mm, inner diameter 0.28 mm) with a volume of 100 μl containing either 1×1011 colony-forming units/ml of C. turicensis or sterile LB medium in the experimental group. Simultaneously, 100 μl of either Cronobacter – mixture of phages (1×1011 plaque-forming units/ml), or sterile PBS were administered intraperitoneally. After 24 h blood, bladder and kidneys were collected under aseptic conditions. Tissues were homogenized in 300 μl of sterile PBS using TissueLyser II (Qiagen, Hilden, Germany), and aliquots were used for cultivation and biochemical analyses.

Biochemical analyses

All chemicals were from Sigma-Aldrich (St Louis, USA), if not otherwise stated. Advanced glycation end-products (AGEs) as markers of carbonyl stress were determined spectrofluorometrically, using the specific fluorescence of Schiff base and Amadori products after addition of phosphate buffer saline (PBS) at λex=370 nm and λem=430 nm directly in homogenate tissues [24]. Thiobarbituric acid reacting substances (TBARS) as a marker of oxidative damage of lipids were determined as described by Ohkawa et al. [25]. Briefly, 20 μl of homogenate, 30 μl distilled H2O, 20 μl of 0.67% thiobarbituric acid (Sigma-Aldrich, Germany) and 20 μl of glacial acetic acid were mixed in 96-well microtitration plate. After 45 minutes of incubation at 94°C (Mastercycle pro S, Eppendorf, Hamburg, Germany), 100 μl of n-butanol (Merck, USA) was added and the absorbance was measured after centrifugation (2000 g/10 min/4°C) in the upper phase at 532 nm. Ferric reducing activity of the tissue (FRAT) as a marker of antioxidant status was measured as described by Erel et al. [26]. Twenty μl of sample was added into 200 μl of freshly prepared FRAT reagent (3 mol/l acetate buffer, pH 3.6; 10 mmol/l of tripyridyl-s-triazine dissolved in 40 mmo/l HCl; 20 mmol/l FeCl3; and 6H2O and H2O in ratio 1:1:1:9, respectively) warmed to 37°C and measured after 4 min of incubation at 593 nm. Proteins were quantified using the Bradford method [27]. As a standard, bovine serum albumin (Fermentas, Vilnius, Lithuania) was used and 5 μl of tissue homogenates were mixed with 250 μl of Bradford reagent (Fermentas, Vilnius, Lithuania). Absorbance was measured at 595 nm after 5 min. All measurements were done on a Sapphire II instrument (Tecan, Grödig, Austria).

Real-time PCR

Total RNA was isolated from tissues using the TriReagent (MRC, Cincinnati, USA). Concentration and purity of isolated RNA was evaluated spectrophotometrically by Nanodrop (Thermo Fisher Scientific, USA). One-step RT real-time PCR with specific primers was used for the relative quantification of gene expression (QuantiTect SYBR green RT-PCR kit, Qiagen, Hilden, Germany). Genes of interest were tumor necrosis factor-alpha (TNF-α; primer F – gtccctttcactcactggcc; primer R – gagtgcctcttctgccagttc) and monocyte chemoattractant protein-1 (MCP-1; primer F – cctacaactttattaaaactgcatctg; primer R - ctagttcactgtcaactggtcactc). Peptidylprolyl isomerase A (PPIA; primer F – ttcgagctctgagcactgg; primer R – ccagtgccattatggcgt) was used as a housekeeping gene.

Statistical analysis

The results were analyzed using the XLStatistics v. 10.05.30 software. Differences between groups were evaluated with ANOVA and post-hoc Student t-test with Bonferroni correction of multiple comparison bias. P-values less than 0.05 were considered significant. Data are presented as mean ± standard deviation.

Results

Electron microscopy of used bacteriophages P2 and D2 showed that both are members of the Podoviridae family, order Caudovirales, with 180±20 nm head diameter and 60±10 nm long non-contractile tail. Host specificity tests were performed on 41 different strains, including Salmonella, E. coli, Citrobacter and Enterobacter cloacae. Neither of these phages was able to infect Citrobacter, Salmonella or E. coli strains. Phages showed different ability to lyse Enterobacter cloacae strains (P2 – 25%, D2 – 38%). Cultivation analysis revealed that bacterial colonies were found only in bladders and kidneys of mice that were injected with Cronobacter cells. Mean bacterial count in the kidney was 734 cfu and phage therapy decreased the count by 70% (Z=3.06; p=0.002, Figure 1A). In the bladder the mean bacterial load was cca 900 cfu in both CRONO and CRONO + PHAGE groups (Z=−0.55; p=0.58; Figure 1B). No significant differences were found between the PHAGE and CRONO + PHAGE groups in the number of phage plaques in the kidney (Z=0.32; p=0.75; Figure 1C), but were higher in the CRONO + PHAGE group, although not significant due to high interindividual variability (Z=−1.53; p=0.13; Figure 1D).
Figure 1

Cultivation analysis of Cronobacter colonies and phage plaques recovered from the kidney and from the bladder. * denotes p<0.01 vs. CRONO.

AGEs in renal cortex as a marker of carbonyl stress were not altered by infection with Cronobacter, but were significantly reduced by phage therapy in comparison to the infected mice (by 57%; t=2.46; p=0.02; Figure 2A). Malondialdehyde as a marker of lipoperoxidation was doubled in the kidneys of infected mice (t=4.15; p=0.0009; Figure 2B) and lowered with phage therapy by 39% (t=2.94; p=0.008; Figure 2B). Groups did not differ in FRAT as a marker of antioxidant status in the renal tissue (Figure 2C). No significant differences were found in any of the analyzed markers of oxidative stress in the bladder (Figure 2D–F).
Figure 2

Oxidative stress markers in the kidney and in the bladder. *** denotes p<0.001 vs. CTRL; * denotes p<0.05 vs. CRONO; ** denotes p<0.01 vs. CRONO.

Analysis of expression of TNF alpha and MCP-1 revealed that both cytokines were upregulated in the bladder of infected mice (TNF alpha by 72%; t=3.02; p=0.007; MCP-1 by 52%; t=3.03; p=0.007). These differences were reduced by phage therapy (TNF alpha by 35%; t=3.58; p=0.002; Figure 3C; MCP-1 by 22%; t=2.53; p=0.02; Figure 3D). In the renal cortex only the infection-induced increase in expression of MCP-1 was significant (by 48%; t=2.57; p=0.02; Figure 3B). The decrease due to phage therapy was significant for TNF alpha (by 36%; t=2.78; p=0.02; Figure 3A).
Figure 3

Analysis of gene expression using real time PCR. * denotes p<0.05 vs. CTRL; ** denotes p<0.01 vs. CTRL; *** denotes p<0.05 vs. CRONO.

Discussion

Although seldom life-threatening, chronic UTI is associated with high morbidity and thus represents a frequent problem in primary care [28]. It even represents a common cause of sepsis in critically ill or otherwise immuno-compromised patients and may be a cause of nonspecific complaints with negative initial urinalysis in the elderly [29]. In most cases, appropriate choice and dosing of antibiotics or chemotherapeutics is sufficient for successful treatment; however, with increasing incidence of UTI caused by resistant strains, the need for alternative options becomes urgent [30]. Bacteriophages as viruses that attack bacteria are such an alternative. Phages with a lytic cycle can be seen as natural antimicrobial agents. Host specificity of phages is high and can be narrowed by genetic engineering or by in vitro evolution and selection [31]. The safety profile seems to be far better in comparison to antibiotics, at least according to already published data. Phage particles do not invade or actively affect eukaryotic cells, but may induce a humoral immune response [18]. Long-term studies dealing with safety of phage administration are, nevertheless, needed [19]. UTI caused by Cronobacter spp. is rather rare [2]. However, UTI in mice is a suitable model for testing the ability of phage therapy to conquer an infection in vivo, mainly due to physiologically sterile environment and a reproducible read-out parameter in the form of renal colonization. Ascending nephritis was partially prevented in our experiment, indicating that the applied phages could be usable in other infection models. This assumption has to be verified in separate studies, as the conditions in the urinary tract differ from those in other organs or tissues. The observed 70% reduction of Cronobacter colonies in the kidneys 24 hours after a single phage dose is consistent with other similar results observing phage efficacy in the treatment of wound infections [32]. The ability of phages to survive in the urinary tract 24 hours after administration has already been shown [33]. There was no difference in Cronobacter colonization of the bladder between treated and infected groups. This might indicate that the kinetics of phages after intraperitoneal administration could be improved by choosing another application route. On the other hand, similar to other studies using the transurethral UTI model, the variance, especially in the cultivation analysis, is high. In addition to simple reproduction of the results, a similar confirmatory experiment is planned on larger experimental animals, including rats, dogs and other vertebrates [23]. According to our knowledge this is the first study showing that phage therapy decreases oxidative stress in urinary tract infection. It has been shown that phage therapy can attenuate the effects of oxidative burst caused by activated phagocytes [34]. Whether the observed reduction in oxidative stress in our experiment is direct or due to reduced inflammation cannot be determined based on the available data. The clinical significance of this antioxidative effect is questionable, but might gain importance in chronic infections where oxidative damage of tissues plays an important role in the pathogenesis.

Conclusions

Data from the presented study show that the phage therapy was effective in the prevention of renal infection in a model of Cronobacter-induced urinary tract infection in mice. Inflammation and oxidative stress were reduced in the kidney and partially reduced in the bladder. Future studies should focus on long-term effects and safety, as well as on the potential use of phage therapy of Cronobacter infections in models of enterocolitis, meningitis or sepsis.
  33 in total

1.  Reaction of linoleic acid hydroperoxide with thiobarbituric acid.

Authors:  H Ohkawa; N Ohishi; K Yagi
Journal:  J Lipid Res       Date:  1978-11       Impact factor: 5.922

2.  A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation.

Authors:  Ozcan Erel
Journal:  Clin Biochem       Date:  2004-04       Impact factor: 3.281

3.  Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA.

Authors:  G Münch; R Keis; A Wessels; P Riederer; U Bahner; A Heidland; T Niwa; H D Lemke; R Schinzel
Journal:  Eur J Clin Chem Clin Biochem       Date:  1997-09

4.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

Review 5.  Enterobacter sakazakii and other bacteria in powdered infant milk formula.

Authors:  Stephen J Forsythe
Journal:  Matern Child Nutr       Date:  2005-01       Impact factor: 3.092

6.  Natural antibiotic susceptibility of Enterobacter amnigenus, Enterobacter cancerogenus, Enterobacter gergoviae and Enterobacter sakazakii strains.

Authors:  I Stock; B Wiedemann
Journal:  Clin Microbiol Infect       Date:  2002-09       Impact factor: 8.067

Review 7.  Microbiological, epidemiological, and food safety aspects of Enterobacter sakazakii.

Authors:  A Lehner; R Stephan
Journal:  J Food Prot       Date:  2004-12       Impact factor: 2.077

8.  Effects of bacteriophages on free radical production and phagocytic functions.

Authors:  Anna Przerwa; Michał Zimecki; Kinga Switała-Jeleń; Krystyna Dabrowska; Ewa Krawczyk; Mirosław Łuczak; Beata Weber-Dabrowska; Danuta Syper; Ryszard Miedzybrodzki; Andrzej Górski
Journal:  Med Microbiol Immunol       Date:  2006-01-31       Impact factor: 3.402

9.  The growth profile, thermotolerance and biofilm formation of Enterobacter sakazakii grown in infant formula milk.

Authors:  C Iversen; M Lane; S J Forsythe
Journal:  Lett Appl Microbiol       Date:  2004       Impact factor: 2.858

Review 10.  Multiresistant bacteria and current therapy - the economical side of the story.

Authors:  Michael H Wilke
Journal:  Eur J Med Res       Date:  2010-11-30       Impact factor: 2.175

View more
  16 in total

Review 1.  Cronobacter sakazakii: stress survival and virulence potential in an opportunistic foodborne pathogen.

Authors:  Audrey Feeney; Kai A Kropp; Roxana O'Connor; Roy D Sleator
Journal:  Gut Microbes       Date:  2014

Review 2.  Biological challenges of phage therapy and proposed solutions: a literature review.

Authors:  Katherine M Caflisch; Gina A Suh; Robin Patel
Journal:  Expert Rev Anti Infect Ther       Date:  2019-12-02       Impact factor: 5.091

3.  A Novel Phage Cocktail Therapy of the Urinary Tract Infection in a Mouse Model.

Authors:  B Mijbel Ali; S A Gatea Kaabi; M A Al-Bayati; H K Musafer
Journal:  Arch Razi Inst       Date:  2021-11-30

4.  A Novel Bacteriophage Targeting Cronobacter sakazakii Is a Potential Biocontrol Agent in Foods.

Authors:  Ju-Hoon Lee; Jaewoo Bai; Hakdong Shin; Yeran Kim; Bookyung Park; Sunggi Heu; Sangryeol Ryu
Journal:  Appl Environ Microbiol       Date:  2015-10-23       Impact factor: 4.792

Review 5.  Semi-Solid and Solid Dosage Forms for the Delivery of Phage Therapy to Epithelia.

Authors:  Teagan L Brown; Steve Petrovski; Hiu Tat Chan; Michael J Angove; Joseph Tucci
Journal:  Pharmaceuticals (Basel)       Date:  2018-02-26

6.  Phage therapy administered noninvasively could be effective in thin tubes subject to episodic flow despite washout: a simulation study.

Authors:  Celia Blanco; Irene A Chen
Journal:  Phys Biol       Date:  2019-07-22       Impact factor: 2.583

7.  Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus.

Authors:  Amy E Kirby
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

Review 8.  A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens.

Authors:  Xavier Wittebole; Sophie De Roock; Steven M Opal
Journal:  Virulence       Date:  2013-08-13       Impact factor: 5.882

9.  Variability in Cell Response of Cronobacter sakazakii after Mild-Heat Treatments and Its Impact on Food Safety.

Authors:  Julio Parra-Flores; Vijay Juneja; Gonzalo Garcia de Fernando; Juan Aguirre
Journal:  Front Microbiol       Date:  2016-04-19       Impact factor: 5.640

10.  Multiplexed Lateral Flow Test for Detection and Differentiation of Cronobacter sakazakii Serotypes O1 and O2.

Authors:  Eva J Scharinger; Richard Dietrich; Tobias Wittwer; Erwin Märtlbauer; Kristina Schauer
Journal:  Front Microbiol       Date:  2017-09-20       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.